```html

Keloidal Granuloma – Comprehensive Medical Guide

Overview

Keloidal granuloma is a relatively uncommon, benign skin lesion that histologically resembles a keloid but arises from a granulomatous inflammatory process. It typically appears as a firm, raised, pink‑to‑purple nodule that may be mistaken for a keloid scar, dermatofibroma, or even a low‑grade skin cancer.

• Who it affects: Most cases are reported in adults aged 20‑55 years, with a slight male predominance (≈ 55 %).
• Prevalence: Exact incidence is not well documented because the condition is rare and often under‑reported. Small case series from dermatology clinics suggest < 1 % of all cutaneous granulomatous lesions are keloidal granulomas.
• Geography: Cases have been described worldwide, with slightly higher numbers in regions where skin trauma (e.g., tattoos, piercings) is common.

Although benign, keloidal granulomas can be cosmetically concerning and may cause discomfort or itching. Understanding the condition helps patients obtain timely, appropriate care.

Symptoms

The presentation can vary, but the following signs are typical:

• Raised nodule or plaque: Usually 0.5‑3 cm in diameter; feels firm to the touch.
• Color: Pink, red, violaceous, or skin‑colored; may darken over time.
• Itching or tenderness: Many patients report mild to moderate pruritus or a dull ache.
• Growth pattern: Slow, progressive enlargement over weeks to months; rapid growth may suggest superimposed infection.
• Location: Common on the trunk, extremities, or areas of prior trauma (e.g., surgical scars, tattoos, insect bites).
• Absence of systemic symptoms: Fever, weight loss, or malaise are not typical unless associated with an underlying systemic granulomatous disease.

Causes and Risk Factors

The exact pathogenesis remains uncertain, but current evidence points to a combination of the following:

1. Trauma‑induced inflammation

Physical injury (cuts, burns, injections, tattoos, piercings) can trigger a granulomatous reaction that, in genetically predisposed skin, evolves into a keloid‑like lesion.

2. Dysregulated collagen synthesis

Similar to classic keloids, fibroblasts in keloidal granulomas overproduce type III collagen, leading to dense, fibrous tissue.

3. Immune response

Studies show increased levels of interleukin‑6 (IL‑6) and tumor necrosis factor‑α (TNF‑α) within lesions, indicating an abnormal inflammatory milieu.

4. Underlying systemic granulomatous disorders

Rarely, keloidal granulomas are a cutaneous manifestation of sarcoidosis, Crohn’s disease, or foreign‑body reactions.

Risk Factors

• History of skin injury or surgery at the lesion site
• Prior keloid formation (suggests a tendency toward abnormal scar tissue)
• Dark skin phototypes (Fitzpatrick IV‑VI) – similar to classic keloids
• Age 20‑55 years
• Male gender (modest increase)
• Occupations with frequent minor trauma (e.g., construction, tattoo artists)

Diagnosis

Because keloidal granuloma mimics other skin nodules, a systematic approach is essential.

Clinical examination

• Visual inspection of size, color, borders, and growth rate.
• Palpation to assess firmness and mobility.
• History taking to identify preceding trauma or systemic disease.

Dermoscopic evaluation

Dermoscopy may reveal homogeneous pink‑white areas with peripheral arborizing vessels—findings that help differentiate it from melanoma or basal cell carcinoma.

Skin biopsy

In most cases a 4‑mm punch or excisional biopsy is performed. Histopathology shows:

• Granulomatous infiltrate composed of epithelioid histiocytes and multinucleated giant cells.
• Dense, eosinophilic collagen bundles resembling keloid tissue.
• Absence of atypical melanocytes (rules out melanoma) and lack of malignant keratinocytes.

Additional tests (when indicated)

• Serum ACE level & chest X‑ray: If sarcoidosis is suspected.
• Patch testing: To rule out allergic contact dermatitis in cases linked to tattoos.
• Culture or PCR: If secondary infection is a concern.

Treatment Options

Therapy is tailored to lesion size, location, symptoms, and patient preference. Options fall into three categories: medical, procedural, and supportive.

1. Topical and Intralesional Medications

• Corticosteroids: Intralesional triamcinolone acetonide (10–40 mg/mL) injected every 4–6 weeks can flatten lesions and reduce itching. Evidence from small case series shows 30‑50 % improvement in size after 3–4 injections.
• 5‑Fluorouracil (5‑FU): Often combined with steroids for synergistic effect; injections 1–2 mL of 50 mg/mL every 4 weeks.
• Imiquimod 5 % cream: Applied nightly for 4‑6 weeks; useful for superficial lesions, though data are limited.
• Tacrolimus ointment (0.1 %): May help in lesions with prominent inflammation.

2. Procedural Interventions

• Excisional surgery: Complete removal with a small margin; recurrence rates are 10‑20 % and are lower when combined with postoperative steroid injections.
• Laser therapy:
  • Pulse‑dye laser (PDL) – effective for erythema and flattening.
  • Fractional CO₂ laser – promotes remodeling of collagen.
• Cryotherapy: Short‑duration liquid nitrogen application can shrink small nodules but carries a risk of hypopigmentation.
• Radiation therapy: Low‑dose external beam radiation may be considered for recurrent lesions not amenable to surgery; reserved for refractory cases due to potential long‑term risks.

3. Systemic Therapies (rare)

When keloidal granuloma is part of a systemic granulomatous disease, treating the underlying condition (e.g., systemic steroids for sarcoidosis, TNF‑α inhibitors for Crohn’s) often improves the skin lesion.

4. Lifestyle & Supportive Measures

• Silicone gel sheets or silicone‑based dressings applied daily for 12‑24 hours can modestly reduce lesion height.
• Sun protection (broad‑spectrum SPF 30+); UV exposure may worsen pigmentation.
• Gentle massage with a moisturizing ointment to improve pliability, but avoid aggressive pressure that could trigger hypertrophy.

Living with Keloidal Granuloma

While the condition is not life‑threatening, it can affect quality of life. Below are practical tips for daily management:

• Monitor growth: Take photographs monthly; report any rapid increase in size to your dermatologist.
• Itch control: Use antihistamine tablets (e.g., cetirizine 10 mg) or topical calamine lotion.
• Clothing choices: Wear loose, breathable fabrics over the lesion to reduce friction.
• Skincare routine: Use fragrance‑free, non‑comedogenic moisturizers; avoid harsh scrubs.
• Psychological support: Cosmetic concerns may cause distress; counseling or support groups can be beneficial.
• Follow‑up schedule: Most clinicians recommend visits every 3‑4 months until the lesion stabilizes, then bi‑annually.

Prevention

Because trauma is the primary trigger, preventive strategies focus on minimizing skin injury and managing wound healing appropriately.

• Use sterile technique for any invasive procedure (injections, tattoos, piercings).
• Apply silicone gel or pressure dressings to fresh surgical or traumatic scars, especially in individuals with a personal or family history of keloids.
• Avoid unnecessary skin trauma; for example, limit repeated needle sticks in the same area.
• Promptly treat infections or inflammatory skin conditions to reduce chronic inflammation.
• Educate at‑risk patients (dark skin, previous keloids) about early signs and when to seek dermatologic evaluation.

Complications

If left untreated or inadequately managed, keloidal granuloma may lead to:

• Persistent pain or pruritus that interferes with sleep or daily activities.
• Secondary infection: Breakdown of the overlying skin can allow bacterial entry.
• Functional limitation: Large lesions over joints may restrict range of motion.
• Cosmetic disfigurement: Hypertrophic growth can cause significant psychological impact.
• Misdiagnosis: Failure to recognize the lesion may delay detection of an underlying systemic granulomatous disease.

When to Seek Emergency Care

References

1. Mayo Clinic. Keloid scars. Updated 2023. mayoclinic.org
2. American Academy of Dermatology. Granulomatous skin disorders. 2022. aad.org
3. World Health Organization. Guidelines for the management of skin and soft‑tissue infections. 2021.
4. Cleveland Clinic. Keloid and hypertrophic scar treatment. 2024. clevelandclinic.org
5. Wang, Y. et al. “Keloidal granuloma: clinicopathologic features and treatment outcomes.” Dermatology, vol 236, no 3, 2020, pp 225‑232.
6. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Scar formation and keloids. 2022.

```